medicines

Investing.com — Shares of Blueprint Medicines (NASDAQ:) Corporation (NASDAQ:BPMC) climbed 17% as the company outlined its growth strategy for 2025, highlighting the potential of its systemic mastocytosis (SM) franchise and positive trial data for its new treatment, BLU-808. Blueprint Medicines, based in Cambridge, Massachusetts, updated its peak revenue estimate for…

By Michael Erman NEW YORK (Reuters) – Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer (NYSE:) COVID-19 treatment Paxlovid, Bristol Myers (NYSE:) Squibb’s cancer cell therapies and vaccines from France’s Sanofi (NASDAQ:) at the start of 2025, according to data analyzed by healthcare research…